OT-202

N/A

Report date: 2026/03/09 20:02:04
NME

Base Information

Drug NameOT-202
Drug Alias NameOT 202OT-202
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein-tyrosine kinases inhibitorsAngiogenesis inhibitorsVascular endothelial growth factor receptor 2 inhibitors
TargetsProtein-tyrosine kinasesVascular endothelial growth factor receptor 2
Therapy Area/IndicationsXerophthalmia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesOcumension (Hong Kong) Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesOcumension (Hong Kong) LtdOcumension Therapeutics (Shanghai) Co LtdZhuhai Essex Bio-Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsXerophthalmia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A